Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
22143
Prostate Cancer Phase I
- 9.4 weeks
- 1st site activated in Canada
22143
Prostate Cancer Phase I
- 13.4 weeks
- 2nd site activated in Canada
22143
Prostate Cancer Phase I
- 13.4 weeks
- 3rd site activated in Canada
221611 (Crown)
HIV Phase IIIb
- 8.6 weeks
- 1st site activated in Canada
223050
Prostate Cancer Phase I/II
- 8.6 weeks
- 1st site activated in Canada
223050
Prostate Cancer Phase I/II
- 11.8 weeks
- 2nd site activated in Canada
223559
Advanced Solid Tumors Phase I/II
- 13.8 weeks
- Canadian FPI
223559
Advanced Solid Tumors Phase I/II
- 14 weeks
223674 (B7H3)
Oncology (Lung Cancer) Phase III
- 8 weeks
22419 (ASSESS)
Genetic Disorder (Alport Syndrome) Phase IIa
- 7 weeks
- 1st site activated in Canada
22419 (ASSESS)
Genetic Disorder (Alport Syndrome) Phase IIa
- 12 weeks
- 2nd site activated in Canada
22776 (exPDite-2)
Parkinson’s Disease Phase III
- 16.4 weeks
- 1st site activated in Canada
300383 (StrateGIST 3)
Gastrointestinal Stromal Tumors (GIST) Phase III
- 8.2 weeks
ACT18421
Chronic Rhinosinusitis Phase II
- 9 weeks
- Canadian FPI
ACT18421
Chronic Rhinosinusitis Phase II
- 14.8 weeks
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
- 6.8 weeks
- Canadian FPI
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
- 6.2 weeks
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
- 7.8 weeks
BGB-11417-304
Chronic Lymphocytic Leukemia Phase III
- 9 weeks
BN44715
Parkinson’s Disease Phase III
- 10.4 weeks
- 1st site activated in Canada
BN44715
Parkinson’s Disease Phase III
- 10.6 weeks
BP41072
Lymphome Phase III
- 14.2 weeks